Delivery Order SPE2DB25D3306-SPE2DB25FUCWJ
- Not listed
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $61,412.92. This competitively awarded, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a $16,346.89 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of July 28, 2025. This firm fixed-price contract, which was competitively awarded without set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through...
- The Defense Logistics Agency awarded a $40,681.37 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This non-set-aside contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $13,364.64 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injections on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price, non-competitive delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's facility...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,006.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen auto-injectors. The contract, executed on July 18, 2025, with an ultimate completion date of July 21, 2025, operates under firm fixed-price terms with no set-aside designation. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a $22,639.98 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract, which is non-set-aside and firm fixed price, will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCWJDelivery Order
The Defense Logistics Agency (DLA) awarded a $38,968.29 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This is a firm fixed price, non-set-aside delivery order with performance through September 5, 2025, and fulfillment from the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, is a critical federal vendor specializing in pharmaceutical procurement for military and veteran healthcare systems. The company's DLA IDC enables it to supply an extensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems worldwide. This specific delivery order for Dupixent, a biologic treatment used for conditions such as atopic dermatitis and eosinophilic asthma, reflects the contractor's role in providing specialized medications to support military medical readiness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.0k | 9/4/25 |